Las Vegas, USA, March 31, 2022 (GLOBE NEWSWIRE) -- Lung Transplant Rejection Pipeline Analysis | Clinical Trials Evaluation Research Report 2022 by DelveInsight
As the number of lung transplants annually in the US and worldwide has increased, so has the occurrence of Lung Transplant Rejection. Key companies are involved in developing a treatment for antibody-mediated Lung Transplant Rejection including Bristol Myers Squibb, Genentech, and several others.
DelveInsight’s ‘Lung Transplant Rejection Pipeline Insight 2022’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Lung Transplant Rejection pipeline domain.
Some of the essential takeaways from the Lung Transplant Rejection Pipeline report:
- DelveInsight’s Lung Transplant Rejection Pipeline analysis depicts a robust space with 7+ active players working to develop 7+ pipeline treatment therapies.
- Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Lung Transplant Rejection treatment scenario include Corline Biomedical, MimeTech, TFF Pharmaceuticals, Kamada, Genentech, Bristol Myers Squibb, and many others.
- Essential Lung Transplant Rejection pipeline therapies such as Renaparin, MT-8, TFF TAC-LAC, Alpha-1 antitrypsin, Pirfenidone, Belatacept, and others are under development in different phases of clinical trials.
- Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down-regulate production of multiple cytokines, and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone is currently being evaluated in Phase II clinical trial for Restrictive Chronic Lung Allograft Dysfunction.
- In June 2015, Kamada Collaborated with Baxalta on a Phase I/II clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection. Under the agreement, Baxalta collaborated in the development and funding of Phase I/II clinical study.
- In July 2016, Kamada initiated the first clinical trial designed specifically to prevent Lung Transplant Rejection, to assess the safety of AAT IV and the effect on rate and severity of acute and chronic Lung Transplant Rejection as well as pulmonary infections, in subjects undergoing first lung transplantation.
- Belatacept selectively blocks the process of T-cell activation. It is currently being investigated in Phase II clinical trials for patients with Lung Transplant Rejection by Bristol-Myers Squibb.
- TFF TAC-LAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine being investigated in the Phase I stage of development for the prevention of Rejection of Organ Transplant.
Request a sample and discover more about the report highlights & offerings @ Lung Transplant Rejection Emerging Therapies
The Lung Transplant Rejection pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Lung Transplant Rejection products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Lung Transplant Rejection pipeline landscape.
Lung Transplant Rejection Overview
Lung transplantation is the ultimate treatment option for patients with end-stage lung disease. As the number of lung transplants annually in the US and worldwide has increased, so has the occurrence of Lung Transplant Rejection. This is due to the systemization of nationwide database and allocation, improved surgical techniques, and the advent of a new generation of immunosuppressants. It can be categorized as hyperacute, acute, and chronic. Acute cellular rejection of lung transplants occurs in up to 90 percent of patients.
Find out more about the disease and recent developments @ Lung Transplant Rejection Pipeline Assessment
Lung Transplant Rejection Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| Renaparin | Corline Biomedical | Preclinical | Endothelial cell modulators | NA |
| MT-8 | MimeTech | Preclinical | Nerve growth factor receptor agonists | NA |
| TFF TAC-LAC | TFF Pharmaceuticals | Phase I | T cell activation inhibitors | Inhalation |
| Alpha-1 antitrypsin | Kamada | Phase II | Serine endopeptidase inhibitors | Intravenous |
| Pirfenidone | Genentech | Phase II | Collagen inhibitors; Cytokine inhibitors | Oral |
| Belatacept | Bristol Myers Squibb | Phase II | CD80 antigen inhibitors | Intravenous |
Learn more about the novel and emerging Lung Transplant Rejection pipeline therapies @ Lung Transplant Rejection Pipeline Analysis
Lung Transplant Rejection Therapeutics Assessment
The Lung Transplant Rejection Pipeline report proffers an integral view of the Lung Transplant Rejection emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
- Coverage: Global
- Therapeutic Assessment By Lung Transplant Rejection Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Lung Transplant Rejection Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
- Therapeutics Assessment By Lung Transplant Rejection Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
- Therapeutics Assessment By Lung Transplant Rejection Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
- Therapeutic Assessment By Lung Transplant Rejection Mechanism of Action: CD80 antigen inhibitors, T cell activation inhibitors, Collagen inhibitors; Cytokine inhibitors, Endothelial cell modulators, Nerve growth factor receptor agonists
- Key Lung Transplant Rejection Players: Corline Biomedical, MimeTech, TFF Pharmaceuticals, Kamada, Genentech, Bristol Myers Squibb
- Key Lung Transplant Rejection Pipeline Therapies: Renaparin, MT-8, TFF TAC-LAC, Alpha-1 antitrypsin, Pirfenidone, Belatacept
Dive deep into rich insights for emerging therapies and assessment, visit @ Lung Transplant Rejection Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Lung Transplant Rejection: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Phase III) |
| 6 | Mid Stage Products (Phase II) |
| 6.1 | Belatacept: Bristol Myers Squibb |
| 7 | Mid Stage Products (Phase II) |
| 7.1 | Pirfenidone: Genentech |
| 8 | Mid Stage Products (Phase II) |
| 8.1 | Alpha-1 antitrypsin: Kamada |
| 9 | Early Stage Products (Phase I) |
| 9.1 | TFF TAC-LAC: TFF Pharmaceuticals |
| 10 | Preclinical Stage Products |
| 10.1 | MT-8: MimeTech |
| 11 | Therapeutic Assessment |
| 12 | Inactive Products |
| 13 | Collaborations Assessment- Licensing / Partnering / Funding |
| 14 | Lung Transplant Rejection- Unmet Needs |
| 15 | Lung Transplant Rejection- Market Drivers and Barriers |
| 16 | Appendix |
| 17 | About DelveInsight |
For further information on the Lung Transplant Rejection pipeline review, reach out @ Lung Transplant Rejection Ongoing Clinical Trials
Related Reports
Non-Small Cell Lung Cancer (NSCLC) Market
DelveInsight’s ‘Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key Non-Small Cell Lung Cancer companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.
Non-Small-Cell Lung Cancer Pipeline
DelveInsight’s, “Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Non-Small-Cell Lung cancer companies involved such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Sanofi, and others.
DelveInsight's "Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Small Cell Lung Cancer market trends, and key Small Cell Lung Cancer companies involved such as Bristol-Myers Squibb, Merck, AstraZeneca, PharmaMar, EpicentRx, and many others.
Small Cell Lung Cancer Pipeline
DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Small Cell Lung Cancer companies involved such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, and others.
"DelveInsight’s ‘Artificial Lung Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Artificial Lung and the historical and forecasted Artificial Lung market trends, and key players involved such as Xenios, Miromatrix Medical, Lung Biotechnology PBC, Haemair, Michigan Critical Care Consultants, MedArray, Breethe, ALung Technologies, McGowan Institute for Regenerative Medicine, and The Charles Stark Draper Laboratory.
Extensive Stage Small Cell Lung Cancer Pipeline
DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Extensive Stage Small Cell Lung Cancer companies such as Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd, Celgene, and others.
Other Trending Reports by Delveinsight
- Tay-Sachs Market
- Reactive Airway Disease Market
- Systemic Sclerosis-associated Interstitial Lung Disease Market
- Epidemic Parotitis Market
- Chronic Myelocytic Leukemia Market
- Congenital Hyperinsulinism Market
- Diabetes Insipidus Market
- Limbal Stem Cells Deficiency Market
- Syncope Market
Interested to know more about the breakthrough happenings? Take a look at the posts below
- Small Cell Lung Cancer Treatment Market Propels Due to Extremely Robust Pipeline
- Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses
- Lung Cancer and its Increasing Global Burden
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
